MA47233A - Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation - Google Patents
Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisationInfo
- Publication number
- MA47233A MA47233A MA047233A MA47233A MA47233A MA 47233 A MA47233 A MA 47233A MA 047233 A MA047233 A MA 047233A MA 47233 A MA47233 A MA 47233A MA 47233 A MA47233 A MA 47233A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- substituted heterocyclic
- compounds used
- heterocyclic compounds
- amine substituted
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436139P | 2016-12-19 | 2016-12-19 | |
| US201762517840P | 2017-06-09 | 2017-06-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA47233A true MA47233A (fr) | 2019-10-23 |
Family
ID=60972416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA047233A MA47233A (fr) | 2016-12-19 | 2017-12-19 | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US20200039998A1 (fr) |
| EP (2) | EP3555070B1 (fr) |
| JP (2) | JP2020504715A (fr) |
| KR (1) | KR102693367B1 (fr) |
| CN (2) | CN110088099B (fr) |
| AU (3) | AU2017382830A1 (fr) |
| BR (1) | BR112019012140A2 (fr) |
| CA (1) | CA3045032A1 (fr) |
| CL (2) | CL2019001664A1 (fr) |
| CO (1) | CO2019006787A2 (fr) |
| DK (1) | DK3555070T3 (fr) |
| ES (1) | ES2955132T3 (fr) |
| FI (1) | FI3555070T3 (fr) |
| HU (1) | HUE063405T2 (fr) |
| IL (1) | IL267090A (fr) |
| LT (1) | LT3555070T (fr) |
| MA (1) | MA47233A (fr) |
| MX (1) | MX2019007234A (fr) |
| PL (1) | PL3555070T3 (fr) |
| PT (1) | PT3555070T (fr) |
| SG (1) | SG10201913464TA (fr) |
| SI (1) | SI3555070T1 (fr) |
| TW (2) | TW202411220A (fr) |
| WO (1) | WO2018118842A1 (fr) |
| ZA (1) | ZA201904234B (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057931A1 (fr) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluorométhoxylation d'arènes via une migration intramoléculaire du groupe trifluorométhoxy |
| AU2017336074A1 (en) * | 2016-09-30 | 2019-03-28 | Epizyme, Inc. | Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors |
| DK3582776T3 (da) | 2017-02-14 | 2024-01-08 | Effector Therapeutics Inc | Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder |
| AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| WO2018195450A1 (fr) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Thérapies d'association avec des inhibiteurs d'ehmt2 |
| ES3002968T3 (en) | 2017-07-14 | 2025-03-10 | Innate Tumor Immunity Inc | Nlrp3 modulators |
| JP7425724B2 (ja) * | 2017-10-17 | 2024-01-31 | エピザイム,インコーポレイティド | Ehmt2阻害剤としてのアミン置換複素環化合物及びその誘導体 |
| AU2018353150B2 (en) * | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| MX2020007152A (es) * | 2017-10-18 | 2020-12-10 | Epizyme Inc | Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos. |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| EP3870178A4 (fr) | 2018-10-24 | 2022-08-03 | Effector Therapeutics Inc. | Formes cristallines d'inhibiteurs de mnk |
| US12509455B2 (en) | 2018-11-07 | 2025-12-30 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as Janus kinase 2 inhibitors and uses thereof |
| EP3876939A4 (fr) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Dérivés benzothiazoles et dérivés 7-aza benzothiazoles comme inhibiteurs de la janus kinase 2 et leurs utilisations |
| WO2020097396A1 (fr) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Dérivés de benzimidazole et dérivés d'aza-benzimidazole en tant qu'inhibiteurs de janus kinase 2 et leurs utilisations |
| EP3911642B1 (fr) * | 2019-01-14 | 2026-06-10 | Innate Tumor Immunity, Inc. | Modulateurs de nlrp3 |
| BR112021016522A2 (pt) | 2019-02-22 | 2021-10-26 | Hanmi Pharm. Co., Ltd. | Composição farmacêutica para o tratamento da leucemia mieloide aguda |
| CN113891749A (zh) * | 2019-03-28 | 2022-01-04 | 埃皮齐梅股份有限公司 | 喹啉衍生物及其用于治疗癌症的用途 |
| EP3991733A4 (fr) | 2019-06-27 | 2023-07-05 | Hanmi Pharm. Co., Ltd. | Composition pharmaceutique pour le traitement de la leucémie myéloïde aiguë contenant un inhibiteur de flt3 et des agents de chimiothérapie |
| CA3156828A1 (fr) | 2019-10-03 | 2021-04-08 | Dana-Farber Cancer Institute, Inc. | Inhibiteurs de kinase tricycliques et leurs utilisations |
| TW202204350A (zh) | 2020-05-06 | 2022-02-01 | 美商雅捷可斯治療公司 | 作為jak2抑制劑之6-雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| EP4267574B1 (fr) | 2020-12-23 | 2025-04-23 | Ajax Therapeutics, Inc. | 6-hétéroaryloxy benzimidazoles et azabenzimidazoles utilisés en tant qu'inhibiteurs de jak2 |
| AU2022281345A1 (en) * | 2021-05-26 | 2023-11-30 | Alkermes, Inc. | Substituted fused bicyclic macrocyclic compounds and related methods of treatment |
| US20240368139A1 (en) * | 2021-10-15 | 2024-11-07 | Tango Therapeutics, Inc. | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
| CA3234638A1 (fr) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-hetero-aryloxy-benzimidazoles et azabenzimidazoles en tant qu'inhibiteurs de jak2 |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| AR129963A1 (es) * | 2022-07-20 | 2024-10-16 | Ildong Pharmaceutical Co Ltd | Compuestos derivados de heteroarilo y usos de los mismos |
| CN115974727B (zh) * | 2023-01-17 | 2024-03-12 | 青岛前线生物工程有限公司 | 一种联苯肼酯的合成方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| AU764479B2 (en) * | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
| US6596747B2 (en) * | 1998-10-29 | 2003-07-22 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| CA2452603A1 (fr) * | 2001-07-03 | 2003-01-16 | Vertex Pharmaceuticals Incorporated | Isoxazolyl-pyrimidines utilisees en tant qu'inhibiteurs des proteines kinases src et lck |
| WO2003040141A1 (fr) * | 2001-09-28 | 2003-05-15 | Bayer Pharmaceuticals Corporation | Composes d'oxazolyl-phenyl-2,4-diamino-pyrimidine, et methodes de traitement de troubles hyperproliferatifs |
| DK1663242T3 (da) * | 2003-08-07 | 2011-08-01 | Rigel Pharmaceuticals Inc | 2,4-Pyrimidindiamin-forbindelser og anvendelse som antiproliferative midler |
| JP2009501164A (ja) * | 2005-07-15 | 2009-01-15 | 4エスツェー アクチェンゲゼルシャフト | 2−アリールベンゾチアゾール及びその使用 |
| ME00011A (fr) * | 2005-12-21 | 2009-02-10 | Novartis Ag | Derives pyrimidinyl-aryluree constituant des inhibiteurs des facteurs de croissance des fibroblastes (fgf) |
| PE20081636A1 (es) * | 2007-01-26 | 2009-01-10 | Smithkline Beecham Corp | Inhibidores de antranilamida para aurora quinasa |
| CN101903357A (zh) * | 2007-07-17 | 2010-12-01 | 里格尔药品股份有限公司 | 作为pkc抑制剂的环状胺取代的嘧啶二胺 |
| KR101247840B1 (ko) * | 2008-02-22 | 2013-03-26 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타 조절제 |
| PL2389372T3 (pl) * | 2009-01-23 | 2016-02-29 | Rigel Pharmaceuticals Inc | Kompozycje i sposoby hamowania szlaku JAK |
| WO2010129802A1 (fr) * | 2009-05-06 | 2010-11-11 | Portola Pharmaceuticals, Inc. | Inhibiteurs de jak |
| WO2014044025A1 (fr) * | 2012-09-20 | 2014-03-27 | 山东亨利医药科技有限责任公司 | Dérivé de pyrimidinamide et son procédé de préparation et son utilisation |
| EP2928891B1 (fr) * | 2012-12-04 | 2019-02-20 | Rigel Pharmaceuticals, Inc. | Inhibiteurs de la protéine kinase c et utilisations de ceux-ci |
| US9169249B2 (en) * | 2013-03-14 | 2015-10-27 | Rigel Pharmaceuticals, Inc. | Protein kinase C inhibitors and uses thereof |
| WO2014152768A1 (fr) * | 2013-03-15 | 2014-09-25 | Portola Pharmaceuticals, Inc. | Composés de cyclohexanediamine et leurs procédés de préparation |
| WO2016175264A1 (fr) * | 2015-04-28 | 2016-11-03 | カルナバイオサイエンス株式会社 | Nouveau dérivé hétéroaryle présentant une activité antipaludique |
| IL307931A (en) * | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| CN106083828A (zh) * | 2016-06-30 | 2016-11-09 | 浙江大学 | 含吖丙啶环侧链的芳胺嘧啶衍生物及制备和应用 |
-
2017
- 2017-12-19 MA MA047233A patent/MA47233A/fr unknown
- 2017-12-19 AU AU2017382830A patent/AU2017382830A1/en not_active Abandoned
- 2017-12-19 CA CA3045032A patent/CA3045032A1/fr active Pending
- 2017-12-19 FI FIEP17829454.2T patent/FI3555070T3/fi active
- 2017-12-19 SG SG10201913464TA patent/SG10201913464TA/en unknown
- 2017-12-19 KR KR1020197020233A patent/KR102693367B1/ko active Active
- 2017-12-19 HU HUE17829454A patent/HUE063405T2/hu unknown
- 2017-12-19 JP JP2019530439A patent/JP2020504715A/ja active Pending
- 2017-12-19 US US16/471,151 patent/US20200039998A1/en not_active Abandoned
- 2017-12-19 EP EP17829454.2A patent/EP3555070B1/fr active Active
- 2017-12-19 WO PCT/US2017/067192 patent/WO2018118842A1/fr not_active Ceased
- 2017-12-19 SI SI201731407T patent/SI3555070T1/sl unknown
- 2017-12-19 BR BR112019012140-4A patent/BR112019012140A2/pt not_active Application Discontinuation
- 2017-12-19 ES ES17829454T patent/ES2955132T3/es active Active
- 2017-12-19 CN CN201780078660.3A patent/CN110088099B/zh active Active
- 2017-12-19 TW TW112121399A patent/TW202411220A/zh unknown
- 2017-12-19 DK DK17829454.2T patent/DK3555070T3/da active
- 2017-12-19 LT LTEPPCT/US2017/067192T patent/LT3555070T/lt unknown
- 2017-12-19 EP EP23186749.0A patent/EP4285906A3/fr not_active Withdrawn
- 2017-12-19 MX MX2019007234A patent/MX2019007234A/es unknown
- 2017-12-19 PT PT178294542T patent/PT3555070T/pt unknown
- 2017-12-19 CN CN202310013963.4A patent/CN116041346A/zh active Pending
- 2017-12-19 TW TW106144660A patent/TWI808067B/zh not_active IP Right Cessation
- 2017-12-19 PL PL17829454.2T patent/PL3555070T3/pl unknown
-
2019
- 2019-06-04 IL IL267090A patent/IL267090A/en unknown
- 2019-06-17 CL CL2019001664A patent/CL2019001664A1/es unknown
- 2019-06-26 CO CONC2019/0006787A patent/CO2019006787A2/es unknown
- 2019-06-27 ZA ZA2019/04234A patent/ZA201904234B/en unknown
-
2020
- 2020-04-29 CL CL2020001133A patent/CL2020001133A1/es unknown
-
2021
- 2021-11-15 US US17/526,058 patent/US20220235065A1/en not_active Abandoned
-
2022
- 2022-04-14 AU AU2022202494A patent/AU2022202494B2/en not_active Ceased
- 2022-05-16 JP JP2022080211A patent/JP2022110080A/ja active Pending
-
2024
- 2024-08-01 AU AU2024205290A patent/AU2024205290A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3402799A4 (fr) | Composés hétérocycliques utilisés comme inhibiteurs du vrs | |
| FR24C1009I2 (fr) | Composés utilisés comme inhibiteurs de kinase | |
| MA55633A (fr) | Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock | |
| MA46045A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA45669A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA44860A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| EP3700527A4 (fr) | Inhibiteurs de papd5 et leurs méthodes d'utilisation | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| MA43284A (fr) | Composés et leurs méthodes d'utilisation | |
| EP3463381A4 (fr) | Dérivés nucléotidiques et leurs méthodes d'utilisation | |
| MA52119A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| EP3681499A4 (fr) | Composés utilisés comme inhibiteurs de ras et leur utilisation | |
| EP3356381A4 (fr) | Dérivés nucléotidiques et leurs méthodes d'utilisation | |
| EP3389783A4 (fr) | Nouveaux composés utilisés comme inhibiteurs de l'indoléamine 2,3-dioxygénase | |
| EP3322409A4 (fr) | Composés aza substitués comme inhibiteurs de l'irak-4 | |
| MA44666A (fr) | Composés aryle ou hétéroaryle à substitution amine utilisés comme inhibiteurs de ehmt1 et ehmt2 | |
| MA50418A (fr) | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse | |
| EP3429591A4 (fr) | Inhibiteurs substitués de ménine-mll et méthodes d'utilisation | |
| MA45116A (fr) | Composés hétérocycliques comme immunomodulateurs | |
| EP3374494A4 (fr) | Compositions crispr et leurs méthodes d'utilisation pour la thérapie génique | |
| EP3373969A4 (fr) | Composés interagissant avec le glycane et méthodes d'utilisation | |
| MA50609A (fr) | Énantiomères de thiazoles substitués utilisés comme composés antiviraux | |
| EP3710006A4 (fr) | Composés hétéroaryle substitués et leurs méthodes d'utilisation | |
| MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine |